Drugs / GST-HG161
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04228406 | Jul 2019 → Sep 2020 | neoplasm | Fujian Cosunter Pharmaceutical Co. Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GST-HG161 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04228406 ↗ |
| Action | Inhibit | “selective c-MET inhibitor” NCT04228406 ↗ |
| Route | Oral | “GST-HG161 will be administered orally to patients once daily” NCT04228406 ↗ |
| Target | MET | “selective c-MET inhibitor” NCT04228406 ↗ |